Literature DB >> 2846019

Hepatitis B and delta markers in primary hepatocellular carcinoma patients in the Gizan area of Saudi Arabia.

S C Arya1, S J Ashraf, C M Parande, M S Tobeiqi, A R Ageel.   

Abstract

Hepatitis B virus (HBV) has been hyperendemic in the Gizan area of Saudi Arabia, located 17 degrees N 43 degrees E, with 20% male and 9% female HBsAg carriers among the native population. Among HBsAg carriers, 8% have been positive for anti-delta antibody while intravenous drug abuse and alcohol have been unknown. Monthly hospitalisation of primary hepatocellular carcinoma (PHC) patients from a catchment population of 500,000 approximates 2-3. HBV markers were tested in 30 PHC cases and compared with 326 otherwise healthy natives. Both HBsAg and total HBV exposure were higher among PHC (p less than 0.001), with no difference between sexes. Anti-delta antibody was demonstrable in 5 of 30 HBsAg-positive PHC with similar distribution among PHC, healthy carriers and those with chronic hepatic disorders. Serum aliquots from 3 hitherto HBV-negative PHC cases are to be tested for HBV-DNA along with immunohistochemical staining on biopsy material. Pending reduction in PHC incidence decades later, subsequent to initiation of HBV immunization, regular examination of HBsAg carriers and established cirrhotics for alphafetoprotein level and ultrasonic hepatic lesions would constitute important interim measures both towards early detection of, and an effective chemotherapy/surgery for, hepatic malignancy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846019

Source DB:  PubMed          Journal:  APMIS Suppl        ISSN: 0903-465X


  9 in total

Review 1.  Therapeutic management algorithm in cirrhotic and noncirrhotic patients in primary or secondary liver masses.

Authors:  Eldo Ermenegildo Frezza
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

2.  Protective Effect of Prosopis cineraria Against N-Nitrosodiethylamine Induced Liver Tumor by Modulating Membrane Bound Enzymes and Glycoproteins.

Authors:  Naina Mohamed Pakkir Maideen; Ravichandiran Velayutham; Gobinath Manavalan
Journal:  Adv Pharm Bull       Date:  2012-06-30

3.  Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients.

Authors:  S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

Review 4.  Immunological treatment of liver tumors.

Authors:  Maurizio Chiriva-Internati; Fabio Grizzi; Cynthia A Jumper; Everardo Cobos; Paul L Hermonat; Eldo E Frezza
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

Review 5.  Hepatitis D: Scenario in the Asia-Pacific region.

Authors:  Zaigham Abbas; Wasim Jafri; Sajjad Raza
Journal:  World J Gastroenterol       Date:  2010-02-07       Impact factor: 5.742

6.  Prevalence of hepatitis d in the eastern mediterranean region: systematic review and meta analysis.

Authors:  Neda Amini; Seyed Moayed Alavian; Ali Kabir; Seyed Hossein Aalaei-Andabili; Seyed Yasser Saiedi Hosseini; Mario Rizzetto
Journal:  Hepat Mon       Date:  2013-01-06       Impact factor: 0.660

7.  Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors.

Authors:  C Niessen; S Thumann; L Beyer; B Pregler; J Kramer; S Lang; A Teufel; E M Jung; C Stroszczynski; P Wiggermann
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

8.  Prevalence and molecular characterization of hepatitis D virus in Saudi Arabia: A single-center study.

Authors:  Ghazi A Jamjoom; Mai M El-Daly; Esam I Azhar; Hind I Fallatah; Hisham O Akbar; Mohammed Babatin; Abdullah S Alghamdi; Mohammed I Dgdgi; Mohamed A Hamid; Yousef A Qari; Sherif A El-Kafrawy
Journal:  Saudi J Gastroenterol       Date:  2017 May-Jun       Impact factor: 2.485

9.  The chemo-prophylactic efficacy of an ethanol Moringa oleifera leaf extract against hepatocellular carcinoma in rats.

Authors:  Kadry M Sadek; Tarek K Abouzed; Reham Abouelkhair; Sherif Nasr
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.